The Food and Drug Administration approved or tentatively approved a record 126 generic drugs in July, the agency reported Thursday, an indication that Republicans are getting the faster approvals they have sought.
The agency approved 96 generic drugs and gave a tentative approval to 30 more in July, according to monthly data. Greater generic competition with pricier brand-name drugs is often thought to be a critical factor in improving drug prices.
Recommended Stories
FDA Commissioner Scott Gottlieb tweeted on Thursday that the total was the highest monthly amount ever in the history of the generic drug program.
[Previous coverage: FDA to call out brand name drug companies that block generics]
GENERIC DRUG NEWS: #FDA beat another record. July saw the highest number of approval actions in the history of the generic drugs program in a single month with 126 total approvals (96 full approvals + 30 tentative approvals) https://t.co/vaSzgrHkyJ pic.twitter.com/t9AUXoicat
— Scott Gottlieb, M.D. (@SGottliebFDA) August 9, 2018
The Trump administration and congressional Republicans often argue that greater generic competition will lower prescription drug prices.
[Also read: Trump teases announcement that will lower prescription drug prices]
Generic approval times have lowered in recent years in part due to the installation of a user fee program through which generic drug companies pay the FDA every time they submit a new application for approval. The FDA in turn uses that money to hire new staff and improve the drug approval process.
The FDA has a goal to review all generic drug applications within 10 months of submission to the agency. Before the first user fee program was implemented in 2012, the agency previously had a backlog of more than 10,000 applications awaiting approval.
